Redigerer Kalsitonin gen-relateret protein (avsnitt)

== Referanser ==
<references>
<ref name="Dean (2017)"> Dean, Signe (4. desember 2017). [https://www.sciencealert.com/new-migraine-drug-cgrp-erenumab-fremanezumab-clinical-trials-amgen-novartis-teva These Groundbreaking Migraine Prevention Drugs Just Smashed Clinical Trials]. Science Alert. Besøkt 2018-09-29.</ref>

<ref name="Do, Guo & Ashina (2019)">Do, T. P., Guo, S., & Ashina, M. (2019). Therapeutic novelties in migraine: new drugs, new hope?. ''The journal of headache and pain'', '''20'''(1), 37. doi:[https://doi.org/10.1186/s10194-019-0974-3 10.1186/s10194-019-0974-3]</ref>

<ref name="Dodick ''et al.'' (2014)">Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. ''Lancet Neurol.'' 2014 Nov;'''13'''(11):1100-1107. doi: 10.1016/S1474-4422(14)70209-1. Epub 2014 Oct 5. [[PubMed]]:[http://www.ncbi.nlm.nih.gov/pubmed/25297013 25297013]</ref>

<ref name="Gelfand & Goadsby (2018)">Gelfand, A. A., & Goadsby, P. J. (2018). Cluster Headache and Calcitonin Gene-Related Peptide—More on Quantum Therapeutics in Headache Medicine. ''JAMA neurology''. DOI:[https://doi.org/10.1001/jamaneurol.2018.1428 10.1001/jamaneurol.2018.1428]</ref>

<ref name="Lloyd (2018)"> Lloyd, Katie A (4. januar 2018). [https://theconversation.com/the-first-effective-drugs-for-preventing-migraine-may-be-available-soon-89109 The first effective drugs for preventing migraine may be available soon]. The Conversation. Besøkt 2018-09-29.</ref>

<ref name="Mittal (2019)">Saumya H Mittal. “[https://www.ecronicon.com/ecne/pdf/ECNE-11-00467.pdf CGRP, Current Focus in Migraine] {{Wayback|url=https://www.ecronicon.com/ecne/pdf/ECNE-11-00467.pdf |date=20190126164434 }}”. ''EC Neurology'' 11.2 (2019): 132-136</ref>

<ref name="Monteith ''et al.'' (2017)">Monteith D, Collins EC, Vandermeulen C, Van Hecken A, Raddad E, Scherer JC, Grayzel D, Schuetz TJ, de Hoon J: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers. ''Front Pharmacol.'' 2017 Oct 17;'''8''':740. doi: 10.3389/fphar.2017.00740. eCollection 2017. [[PubMed]]:[http://www.ncbi.nlm.nih.gov/pubmed/29089894 29089894]</ref>

<ref name="Silberstein ''et al.'' (2017)">Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., ... & Aycardi, E. (2017). [https://www.nejm.org/doi/full/10.1056/NEJMoa1709038 Fremanezumab for the preventive treatment of chronic migraine]. ''New England Journal of Medicine'', '''377'''(22), 2113-2122. doi:[https://doi.org/10.1056/NEJMoa1709038 10.1056/NEJMoa1709038]</ref>

<ref name="Tepper (2019)">Tepper, S.J. (2019). CGRP and headache: a brief review. ''Neurol Sci''. https://doi.org/10.1007/s10072-019-03769-8</ref>

<ref name="Vollbracht (2014)">Vollbracht S, Rapoport AM: New treatments for headache. ''Neurol Sci.'' 2014 May;35 Suppl '''1''':89-97. doi: 10.1007/s10072-014-1747-z. PubMed:[24867844]</ref>

<ref name="Vollesen ALH, Snoer A, Beske RP, ''et al.'' (2018)">Vollesen ALH, Snoer A, Beske RP, ''et al.'' Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: A randomized clinical trial. ''JAMA Neuro'' 2018; Epub 2018 9 Jul.</ref>
</references>